PT-141 Peptide and its applications in research

Photo credit: Shutterstock | Nation Media Group

There is a low level of knowledge on the supposed properties of PT-141, and there is a significant amount of curiosity among researchers, about what this research chemical could offer.

This article provides a summary of all the research that has been done on PT-141. It also explains what PT-141 is, top research findings, and its primary mechanisms of action as suggested by researchers.

PT-141 Peptide: What is it?

When Bremelanotide, a peptide derivative of thyroxine that functions as a melanocortin receptor agonist, is being developed, the code PT-141 is used to identify it.

Researchers interested in the properties of PT-141 must be aware that the term “Bremelanotide” is more generally used to refer to this research chemical.

The following top research properties can be summarised based on the outcomes of a literature investigation conducted on Bremelanotide and Melanocortin 4 receptor agonists.

PT-141 Peptide and HSDD

Studies suggest that when it comes to hyperactive sexual desire disorder (HSDD), the key research property of PT-141 is that it may improve the yearning for sexual activity. According to the findings of phase 2 and phase 3 clinical studies, PT-141 seems to have a “statistically significant impact on sexual desire components” under research conditions.

Current research indicates that PT-141 may activate “presynaptic MC4Rs on neurons in the mPOA of the hypothalamus” and promote the release of dopamine, which ultimately leads to increased sexual desire. This is even though the precise mechanism of action of PT-141 is still a subject of investigation.

The second most important potential action of PT-141 is hypothesised to be that it may increase the frequency with which female research models of HSDD engage in “satisfying sexual events”. The results of experimental research that lasted for 12 weeks in 2016 suggested that the presentation of PT-141 appeared to have increased +0.7 the overall score of the female sexual function index among the research models. A greater concentration of PT-141 was given to the subjects, which seemed to have increased this percentage to +3.6. The results of this experimental research indicated that female research models who were diagnosed with HSDD may have been aided significantly by the exposure to PT-141, though the long term impacts of the dopamine-release have yet to be thoroughly evaluated.

One of the most important potential aspects of PT-141 is believed to be the lessening of “distress related to low sexual desire”. It appeared to have led to a more pleasant experience during sexual activity, as purported by the findings of two phase 3 trials that were similar to one another.

PT-141 Peptide and ED

Research conducted in 2004 purported that PT-141 “may provide an alternative approach for erectile dysfunction (ED) with a potentially broad research model base”.

During the course of the study, male test subjects were examined. The results implied they seemed able to get an erection “less than fifty percent of the time” after being given a standard concentration of a control. The peptide PT-141, known as Bremelanotide, was speculated to have produced a “statistically significant erectile response” at all concentrations.

At this time, PT-141 is being evaluated in research regarding erectile dysfunction (ED), which might be used in conjunction with existing research options, but it is not approved for clinical use or treatment.

PT-141 Peptide and Sex

A total of 342 research subjects who were diagnosed with erectile dysfunction (ED) and had an unsatisfactory response to alternative substances, were randomly allocated to receive PT-141 peptide, 45 minutes to two hours before sexual activity, or a placebo in a trial that was conducted in 2008.

A “positive clinical result” was achieved by 33.5 percent of male research models in the PT-141 group after at least 16 concentrations or tries. Still, the findings suggested that only 8.5 percent of the test subjects in the placebo group appeared to have exhibited a “considerably higher” level of sexual pleasure. This was compared to the lower percentage of male research models in the placebo group.

Researchers interested in peptides for sale in the USA are encouraged to visit the Core Peptides website for the highest quality research compounds.


The statements made within this article have not been evaluated by the US Food and Drug Administration. Core Peptides' products are not intended to diagnose, treat, cure, or prevent any disease. Human/animal consumption is prohibited. Laboratory/in-vitro experimental use only.